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Cytomegalovirus (CMV) infection exerts an enormous effect on human immunity, as it is associated with an immune-impaired
response, a variety of chronic diseases, and overall survival in elderly individuals. Levels of anti-CMV antibodies may be associ-
ated with the differentiation degree of T cell subsets. Titers are significantly higher in the elderly and positively correlated with
specific CD4 T cell responses to CMV. In the elderly, antibody titers are associated with the degree of differentiation and the T
cell receptor excision circle (TREC) content in CD4 T cells, with other features of the immune risk profile, and with a reduced
ability to respond to immunization in vivo. Associations may be absent in young subjects because their anti-CMV antibody ti-
ters are lower than those of the elderly. However, comparing young and elderly individuals with similar antibody levels reveals
differences in their highly differentiated and naïve T cells. These are more marked in individuals with high titers. In parallel with
the increase in anti-CMV antibodies, the elderly experience a significant reduction in absolute counts of naïve CD4 T cells,
which may be a strategy to compensate for the expansion of differentiated cells and to avoid an increase in total T cells. In sum-
mary, our results show that titers of anti-CMV antibodies, and not only CMV seropositivity, are related to differentiation status
and immunocompetence in the elderly, making this as an important prognostic marker of the status of immune system function.
The betaherpesvirus cytomegalovirus (CMV) is a persistent ac-tivating virus that primarily resides in the myeloid cell com-
partment but also spreads to other cell types. Clinically, infection
is considered essentially asymptomatic in immunocompetent
hosts. However, immunosuppressed individuals may suffer seri-
ous consequences as a result of viral reemergence. After infection,
the virus establishes lifelong latency within the host and periodi-
cally reactivates. Reactivation from latency is a key step in the
pathogenesis of the infection and can be detected in response to
inflammation, infection, stress, or immunosuppression (1, 2). Ac-
tivation of protein kinase C and NF-B by tumor necrosis factor
alpha (TNF-) and increasing concentrations of cyclic AMP by
stress hormones and prostaglandins promote viral reactivation
and replication. Reactivation of CMV is more frequent in the el-
derly, as demonstrated by the direct detection of CMVDNA in the
urine. Although reactivation is frequent in the elderly, it is sub-
clinical in nature (3).
Recently, CMV has been linked to a variety of chronic diseases
with an inflammatory component, including cardiovascular dis-
eases, cancer, and cognitive and functional impairment (4–7). The
specific mechanisms responsible for these associations have not
been fully determined but are likely to have an inflammatory and
immune component. Reactivation may result in increased levels
of proinflammatory molecules such as interleukin 6 (IL-6),
TNF-, and C-reactive protein (CRP). In fact, CMV has been
associated with a significantly greater risk of all-cause mortality
and cardiovascular disease-related mortality in subjects with high
CRP levels (8). Longitudinal aging studies suggest that CMV se-
ropositivity is associated with a cluster of immune parameters, the
“immune risk profile” (IRP), which predicts 2-year mortality in a
population-based sample of Swedish octogenarians (9). More-
over, CMV seropositivity is also associated with the phenomenon
of immunosenescence, which is characterized by clonal expansion
of T cells, mainly CD8 T cells, with a highly differentiated cell
surface phenotype and with the acquisition of new functional fea-
tures. Moreover, the hallmark of human immunosenescence, ir-
respective of its association with CMV, is low numbers of naïve T
cells, particularly CD8 T cells, and a corresponding lower diver-
sity of the T cell receptor (TCR) repertoire (10, 11). This has been
proposed as an explanation for much of the decreased ability of
the elderly to resist new infections and to respond effectively to
reinfection and persistent infections (12). Indeed, despite the ev-
idence suggesting that CMV induces aging of T lymphocytes,
more frequent and/or intensive reactivations in the elderlymay be
a consequence rather than the cause of immunosenescence. A
general result of these alterations is that adaptive immunity seems
to weaken with age, whereas innate immunity is maintained or
even enhanced. This may be one of several explanations for the
commonly reported increase in proinflammatory status in the el-
derly, which itself is associated with frailty and mortality (13).
The frequency of CMV seropositivity in the elderly in devel-
oped countries is above 80%. In spite of the enormous impact of
CMV infection onhuman immunity, the degree of immunosenes-
cence varies greatly, as is apparent even when only CMV-infected
individuals are studied (14). We postulate that the humoral re-
sponse to CMV may be a consequence of deleterious changes in
the immune system and may be related to other changes induced
in the immune response, rather than merely infection per se. To
investigate this, we studied the association between anti-CMV an-
tibody titers and various characteristics that define the degree of
differentiation and the functional abilities of the T cell fraction.
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MATERIALS AND METHODS
Study population. Blood samples for hematological and immunological
analyses were obtained from 92 healthy elderly donors (70 females and 22
males) living in the Santa Teresa nursing home (Oviedo, Spain). To en-
sure that a representative sample of the population was studied, volun-
teers were not rigorously selected with respect to their health status. Ex-
clusion criteria were conditions with a possible influence on the immune
system, such as recent or current infection, inflammation, autoimmune
or malignant disease, malnutrition, abnormal laboratory data, and phar-
macological interference (steroids, nonsteroidal anti-inflammatory
agents, and immunosuppressive drugs). Samples from 70 young healthy
controls (24 females and 46 males) were obtained from the Centro de
Transfusiones del Principado de Asturias (Oviedo, Spain). Inclusion cri-
teria were a minimum age of 65 years for the elderly group and a maxi-
mum age of 50 for the young group. The mean age of the elderly individ-
uals was 85.1  6.3 years (range, 68 to 97 years), and that of the young
controls was 38.7 8.4 years (range, 20 to 50 years).
Informed consentwas obtained frompatients and controls before they
participated in the study. The Hospital Universitario Central de Asturias
Ethics Committee (Oviedo, Spain) gave ethical approval for the study.
CMVand influenza virus serology. Levels of CMV-specific immuno-
globulin G (IgG) antibodies were determined by the enzyme-linked im-
munosorbent Vir-ELISA anti-CMV IgG assay (Viro-Immun Labor-Diag-
nostika GmbH, Oberursel, Germany), carried out in accordance with the
manufacturer’s specifications.
Anti-influenza virus antibodies in serum obtained from elderly indi-
viduals were measured by enzyme-linked immunosorbent assay (ELISA)
as previously described (15). The optical density (OD) values of individual
samples were compared against a calibration curve comprising the OD
values of serial dilutions of the same internal control serum from a healthy
vaccinated young person throughout the experiments. Results are ex-
pressed as arbitrary units. The antibody titer decreased significantly with
time since vaccination, so these values were normalized by adjusting the
titer by the time elapsed since immunization.
Hematological analysis and immunological phenotyping.Hemato-
logical parameters were determined with a Sysmex XT-2000i analyzer
(Sysmex,Hamburg-Norderstedt, Germany). The results of the cytometric
studies were analyzed using a FACSCalibur cytometer with CellQuest
software (BD Biosciences, San Jose, CA). EDTA-treated peripheral blood
was surface stained with the following antibodies (antibody labels are in
parentheses): anti-CD8 (phycoerythrin [PE]), anti-CD45RA (fluorescein
isothiocyanate [FITC]) (Immunostep, Salamanca, Spain), anti-CD4
(peridinin chlorophyll protein [PerCP]), anti-CCR7 (Alexa Fluor 647),
anti-CD3 (FITC) (BD Biosciences), and anti-CD28 (PE) (eBioscience,
San Diego, CA). One hundred microliters of whole blood from elderly
individuals was stained with different combinations of labeled monoclo-
nal antibodies (MAbs) for 20 min at room temperature. Samples were
red-blood lysed with FACS lysing solution (BD Biosciences), washed in
phosphate-buffered saline (PBS), and analyzedwithCellQuest software in
the FACSCalibur cytometer. Appropriate isotype controlMAbswere used
for marker settings. In the study of the parameters associated with immu-
nosenescence, staining was performed with anti-CD3 (FITC), anti-CD28
(PE), anti-CD4 (allophycocyanin [APC]) (eBioscience), and anti-CD8
(PerCP). Frequencies of CD4 and CD8 T cells were quantified into
gatedCD3T cells, and those of CD8CD28null andCD4CD28null cells
were gated into CD3 CD8 and CD3 CD4 T cells, respectively.
Activation studies. CMV-infected cell lysate was prepared by infect-
ing human embryonic lung fibroblasts with the AD169 strain of CMV,
and viral titers in the supernatant were determined by standard plaque
assays (viral stock, 105 PFU/ml). The virus was inactivated by five freeze-
thaw cycles.
Activation of T lymphocytes from heparinized whole blood by anti-
CD3 or CMV extract was assessed by surface staining with anti-CD69
(eBioscience). Briefly, heparinized whole blood (250 l) was stimulated
with soluble anti-CD3 (10 ng/ml) (eBioscience) or with the CMV super-
natant (dilution, 104 PFU/ml) in 15-ml conical polypropylene tubes for 18
h at 37°C in an atmosphere of 5% carbon dioxide. After stimulation, cells
were stained with anti-CD69 and anti-CD4 monoclonal antibodies.
Proliferation cultures.To determine the proliferation status of CD4
T cells, peripheral blood mononuclear cells (PBMCs) were isolated by
centrifugation on Ficoll-Hypaque gradients (Lymphoprep; Nycomed,
Oslo, Norway). PBMCs were resuspended in PBS at a final concentration
of 5 106 to 10 106 cells/ml and incubated with 1.5 M carboxyfluo-
rescein succinimidyl ester (CFSE; Invitrogen, Paisley, United Kingdom)
for 10 min at 37°C, washed with RPMI 1640 medium containing 2 103
M L-glutamine and HEPES (BioWhittaker, Verviers, Belgium) twice, and
cultured at 1 106 cells/ml in the presence of soluble anti-CD3 (10 ng/ml)
and CMV extract (104 PFU/ml). The proliferative responses of CD4 T
cells were analyzed on day 7 using a FACSCalibur after staining with
anti-CD4.
TREC quantification.DNAwas extracted from isolated CD4 T cells
(90% purity) from PBMCs using a QIAamp DNA minikit (Qiagen
GmbH, Hilden, Germany), according to the manufacturer’s instructions.
To isolate CD4T cells, PBMCswere isolated by centrifugation on Ficoll-
Hypaque gradients (Lymphoprep) after 20 min of incubation with
RosetteSep human CD4 T cell enrichment cocktail (StemCell Tech-
nologies, Grenoble, France). Signal-joint TREC was quantified by
SYBR green real-time quantitative PCR and an iCycler thermocycler
(Bio-Rad; Life Science Research Group, Hercules, CA), as previously de-
scribed (16). Experimental samples were run in duplicate, and the repli-
cate average was used as the sample result.
HLA-DRB1 typing.HLA-DRB1 alleles were typed, in accordancewith
the manufacturer’s protocols, using Lifecodes HLA-SSO typing kits
(Tepnel Lifecodes Corporation, Stamford, CT) based on the Luminex
Corporation’s X-Map technology.
TNF- promoter polymorphism genotyping. Single nucleotide
polymorphisms (SNPs) at position308 of the TNF- gene were deter-
mined by analyzing the melting temperature (Tm) of the probe/target
duplex after PCR amplification and hybridization with fluorescently la-
beled probes matched with one sequence variant (LightCycler; Roche
Diagnostics, Mannheim, Germany). The primers used were CCTGCATC
CTGTCTGGAAGTTA and CTGCACCTTCTGTCTCGGTTT. The hy-
bridization probes (designed by TIBMolbiol, Berlin, Germany) usedwere
AACCCCGTCCCCATGCCCC-F and LC Red 640-CCAAACCTATTGC
CTCCATTTCTTTTGGGGAC.
Cytokine quantification.Cytokine levels weremeasured in the sera of
elderly subjects using X-Map technology with a Milliplex map kit (Milli-
pore, Billerica, MA), according to the manufacturer’s specifications. This
bead-based analyte detection system was used to quantify human TNF-
and IL-15 using the Luminex Corporation’s X-Map technology.
Statistical analysis. Groups were compared by the nonparametric
Mann-WhitneyU andKruskal-Wallis tests (for non-normally distributed
data) or by Student’s independent-samples t test (for normally distributed
data). Correlations between variables were assessed by the nonparametric
Spearman rho test. The 	2 test was used to compare dichotomous vari-
ables, andmultiple linear regression was used to consider variables simul-
taneously. Analyses were performed using SPSS 15.0 (SPSS Inc., Chicago,
IL). Significance was concluded for P values of
0.05.
RESULTS
CMV seropositivity and antibody titers in young and elderly
people.The characteristics of the individuals enrolled in the study
are shown inTable 1.Wequantified levels of anti-CMVantibodies
in the sera of the 70 young and 92 elderly donors. The frequencies
of seropositivitywere 52%and 91%, respectively (Fig. 1A) (	2 test;
odds ratio [OR], 9.64 to 22.8; P 
 0.001). Levels of anti-CMV
antibodies in seropositive individuals were significantly higher in
elderly than in young individuals, with medians of 1,625 VIRO
units (VU)/ml (interquartile range [IR], 586 VU/ml) and 1,150
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VU/ml (IR, 535.5 VU/ml), respectively (Mann-Whitney U test; P

 0.001) (Fig. 1B).
Aging was associated not only with the percentage of CMV
seropositivity but also with the levels of anti-CMV antibodies.
Correlation between anti-CMV-specific T cells and antibody
titer. To analyze whether individuals with higher anti-CMV anti-
body titers also have stronger CMV-specific T cell responses, the
CD4 T cell response was measured by stimulating whole-blood
cultures with CMV antigens and with anti-CD3. CD69 expression
in response to CMV extracts and to anti-CD3 was analyzed in
CD4 T cells. The magnitude of the CD4 T cell immune re-
sponses to CMV was positively correlated with anti-CMV anti-
body titers in the elderly (Spearman test; rho  0.490 and P 
0.002) (Fig. 1C) but not in young donors (data not shown). No
correlations were found between antibody titers and activation in
response to anti-CD3 in CD4T cells in elderly subjects (Fig. 1C).
Similarly, when proliferative responses were quantified in PBMC
cultures, there was a significant correlation with CD4 T cell pro-
liferation only in the elderly group in response toCMV(Spearman
test; rho 0.516 and P 0.01) but not in response to anti-CD3
(Fig. 1D). No correlations were found between activation or pro-
liferation in CD4T cells with anti-CMV antibody titers in young
donors (data not shown).
Levels of anti-CMVantibodies andCMV-specificCD4T cells
were clearly related in elderly individuals.
T cell differentiation subsets and anti-CMVantibody titer. It
is widely accepted that the progressive deterioration of the T cell
compartment with advancing age is related to CMV seropositiv-
ity. T cells can be separated into functionally distinct populations
using combinations of cell surface markers such as CD45RA and
CCR7. We used these markers to classify the T cells into naïve
(CD45RA CCR7), central memory (CM; CD45RA CCR7),
effector memory (EM; CD45RA CCR7), and effector memory
RA (EMRA; CD45RACCR7) groups (17).Wewanted to verify
TABLE 1 Characteristics of the study subjects
Parametera
Elderly donors
(n 92)
Young donors
(n 70)
Demographic data
Age (yrs)
Mean SE 85.1 6.3 38.7 8.4
Range 68–97 20–50
No. of subjects investigated
Women 70 24
Men 22 46
Hematology values (means SDs)
RBCs (106/l) 4.28 0.63 5.19 0.71
Hemoglobin (g/dl) 13.0 1.89 14.76 1.17
Hematocrit (%) 39.19 5.6 44.06 2.87
MCV (fl) 91.78 6.47 90.6 3.7
Platelets (103/l) 221.65 71.08 312.56 62.44
WBCs (103/l) 6.30 1.80 7.54 1.53
Neutrophils (103/l) 3.67 1.32 4.18 0.98
Monocytes (103/l) 0.53 0.36 0.46 0.25
Lymphocytes (103/l) 1.84 0.68 3.0 0.76
a RBCs, red blood cells; MCV, mean corpuscular volume; WBCs, white blood cells.
FIG1 Frequencies of CMV infection and titers of anti-CMVantibodies in young and elderly subjects and response of CD4T cells from elderly subjects to CMV
and anti-CD3. Immunoglobulin G levels of CMV-specific antibodies were determined by ELISA and a semiquantitative diagram was used to calculate the CMV
titer. (A) Histograms show the percentages of CMV-seropositive (black bars) and CMV-seronegative (white bars) young (n 70) and elderly (n 92) subjects.
The calculated titers of the patient samples are indicated as VIRO units (VU). Percentages of CMV-infected individuals were compared using the 	2 test. (B)
Titers of anti-CMVantibodies in infected young (n 37) and elderly (n 82) subjects are illustrated in the box plots. Significant group differences, assessedwith
theMann-Whitney U test, are indicated. (C andD) CD69 expression and proliferative capacity of CD4T cells from elderly subjects in response to CMV in vitro
stimulation were analyzed. (C) Correlation between anti-CMV antibody titers and the frequency of CD69 expression in CD4 subsets from elderly individuals
in response to a CMV supernatant (104 PFU/ml) (n  37) and to anti-CD3 (10 ng/ml) (n  22). Whole blood from CMV-seropositive elderly people was
stimulated for 18 h. (D) Proliferative capacity of CD4 T cell subsets in response to CMV stimulation (n 28) and to anti-CD3 (n 27). PBMCs were labeled
with CFSE (1.5M) and cultured in the presence of CMV supernatant or anti-CD3 for 5 days. The percentage of dividing CD4T cells is represented. Spearman
correlation coefficients and corresponding P values are presented in the upper left-hand corner. n.s., not significant.
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the association between CMV seropositivity and the degree of
differentiation of T cell subsets in young and elderly individuals.
First, we compared the distributions of the T cell subpopulations
in seropositive and seronegative individuals and found that CMV
seropositivity was related to the reduced frequency of undifferen-
tiated subsets, naïve and CM, only in the CD4 T cells of elderly
individuals (Fig. 2A). No differences were found in the CD8 T
cells from elderly people. Most CD8 T cells belonged to the EM
and EMRA subsets, which are the final stages of differentiation
(data not shown). Moreover, the frequencies of the four popula-
tions were similar in young seropositive and seronegative subjects
in CD4 and CD8 T cells (data not shown).
We then calculated the correlation between the anti-CMV
antibody titer and the frequency of these T cell subsets. We
were unable to demonstrate any associations in young people,
but the effect was evident in CD4 T cells in elderly individuals.
In fact, the frequency of naïve and CM CD4 T cells showed a
significant negative correlation with antibody titers (Spearman
test; rho  0.443 and P 
 0.001 and rho  0.312 and P 
0.005, respectively) (Fig. 2B). On the other hand, the more
differentiated EM subset showed a significant and progressive
increase (Spearman test; rho  0.272 and P  0.014), and no
effect on the proportions of EMRA was found (Fig. 2B). Again,
frequencies of CD8 T cell subsets were independent of the
antibody titers (data not shown).
To examine the differences in the differentiated status of CD4
subsets in CMV-seropositive individuals further, we assessed the
replicative history of these cells by quantifying the content of T cell
receptor excision circles (TREC) in CD4 T cells. TREC consti-
tute a traceablemolecularmarker produced in newly naïve T cells;
the content of TREC in peripheral T cells is an indicator of the
number of divisions that the cell has undergone (18). The analysis
FIG 2 Distribution of CD4 T cells into naïve (CD45RA CCR7), central memory (CD45RA CCR7), effector memory (CD45RA CCR7), and effector
memory RA (CD45RA CCR7) related to CMV seropositivity and anti-CMV antibody titers in elderly subjects. CD45RA and CCR7 expression was analyzed
by flow cytometry in gated CD3 CD4 T cells. (A) Individual segments of the pie charts show the proportions of each subset in CMV-seronegative and
CMV-seropositive elderly subjects. Representative dot plots of the subsets defined by CD45RA and CCR7 expression for individuals in each group show the
percentages of positive cells. Student’s t test or the Mann-Whitney U test was used to examine differences between the groups, and P values are represented. (B)
Relationship between anti-CMV antibody titers and frequency of the CD4T cell populations defined by CD45RA andCCR7 expression. (C) TREC content was
measured inCD4T cells from young (n 25) and elderly (n 30) CMV-seropositive subjects. The CD4 populationwas isolated bymagnetic bead separation
and the TREC copy number was determined by real-time PCR. Experiments were conducted in duplicate, and the results are presented relative to anti-CMV
antibody titers in each subject. Spearman correlation coefficients and corresponding P values are shown in the upper left-hand corner.
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revealed significant differences inTREC content depending on the
levels of anti-CMV antibodies in elderly patients (Spearman test;
rho0.444 and P 0.03) and a nonsignificant trend in young
individuals (Fig. 2C).
In conclusion, both CMV seropositivity and antibody titers
influenced the degree of CD4T cell differentiation in the elderly,
without affecting their CD8 T cells, and the degree of differenti-
ation in CD4 and CD8 T cells of young people.
IRP parameters. CMV infection is considered a predictor of
survival in very elderly people, but we wanted to evaluate the as-
sociation of CMV serological statuswith the other parameters that
define the IRP, the CD4/CD8 ratio and the frequency of CD8
CD28null T cells (9, 19). The CD4/CD8 ratio was slightly lower in
seropositive than in seronegative young (Fig. 3A) and elderly (Fig.
3B) individuals, although neither was statistically significant.
However, a significant negative association between anti-CMV
antibody titers and theCD4/CD8 ratiowas found in elderly people
(Spearman test; rho  0.235 and P  0.033) (Fig. 3C). Con-
versely, the proportion of CD8 CD28null T cells was higher in
CMV-seropositive than CMV-seronegative individuals among
both the young and elderly subjects (Fig. 3A and B) (Student’s t
test; P
 0.001 and P 0.045, respectively) but was not correlated
with the levels of antibodies (Fig. 3C).
Since we had demonstrated that differences in the differentia-
tion status of CD4 T cells are related to CMV infection, we pro-
ceeded to analyze the relationship between the virus and the abun-
dance of CD4 CD28null T cells. As expected, young and elderly
CMV-seropositive people had the highest percentages of CD4
CD28null T cells (Fig. 3A and B) (Mann-Whitney U test; P
 0.001
and P 0.003, respectively). Furthermore, this subset was signif-
icantly increased with higher levels of anti-CMV antibodies in the
elderly (Spearman test; rho 0.348 and P 0.002), but not in the
young (Fig. 3C).
Anti-CMV antibody titers were related to other parameters of
IRP and to CD4 CD28null T cells in the elderly but not in young
individuals.
Comparisons between young and elderly individuals with
similar anti-CMV antibody titers. The lack of correlation be-
tween anti-CMV antibodies and other aspects of immunosenes-
cence in the young but not in elderly people may be because the
antibody levels in the elderly are much higher than in young indi-
viduals. To check whether the profile of cell differentiation found
in these groups was due solely to these differences in the antibody
titer, we compared the degrees of cell differentiation between
young and elderly individuals with similar anti-CMV antibody
titers. Individuals were classified into groups defined according to
their CMV serological status and the antibody levels in young
people, as shown in Fig. 4A (group 0, seronegative; group 1,50th
percentile in young individuals; group 2, between 50th and
95th percentiles in young people; group 3, 95th percentile in
young people).
As there were too few young individuals (only three) in group
FIG 3 Relationship between CMV seropositivity and anti-CMV antibody titer with CD4/CD8 ratio and percentages of CD8 CD28null and CD4 CD28null T
cells in young and elderly subjects. CD4/CD8 ratio and percentages of CD8CD28null andCD4CD28null T cells were compared betweenCMV-seropositive and
CMV-seronegative young (A) and elderly (B) subjects. Significant differences are indicated (Student’s t test or Mann-Whitney U test). (C) Correlation of
anti-CMV antibody titers and CD4/CD8 ratio and percentages of CD8CD28null and CD4CD28null T cells in young (black squares) and elderly (white circles)
subjects are represented in the dot plots. Spearman correlation coefficients and corresponding P values are listed on the right-hand side.
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3 to carry out any meaningful statistical analysis, they were ex-
cluded, so only the elderly individuals in the group were consid-
ered. The median anti-CMV antibody titer in each group did not
differ between elderly and young people. The mean ages of the
elderly individuals were 82.5 8.5 years in group 0, 86 5.5 years
in group 1, 85.5 6.3 years in group 2, and 87 5.6 years in group
3. For the young individuals, the mean ages were 38 7.2 years in
group 0, 41 10 years in group 1, and 42 9 years in group 2.
Frequencies of CD4 CD28null and naïve CD4 T cells in el-
derly and young CMV-seronegative individuals (group 0) were
very similar, but the differences were progressively greater in the
groups with higher antibody levels. This pattern arose mainly be-
cause of the variations experienced by these cellular subsets in the
elderly groups (Fig. 4B). On the other hand, in the case of CD8T
cells, differences were observed between young and elderly indi-
viduals in all groups (Fig. 4B). There were no changes in the dif-
ferences in the frequency of CD28null subsets, while differences in
naïve subsets diminished in the groups with higher anti-CMV
antibody titers. The reason for this in the latter case was the reduc-
tion in the number of naïve cells in young people, since their
frequency in the elderly was very low in all groups.
The frequency of naïve CD4 T cells was related to CMV sero-
logical status and to anti-CMV antibody titers in elderly people
but showed no association in young individuals. We checked
whether this effect merely reflects the increase in the number of
more differentiated cells, a consequence of which is a reduction in
the frequency of naïve cells in the CD4 T cell compartment. We
compared the absolute counts of CD28null and naïve subsets in
CD4 and CD8 T cells in the elderly groups (Fig. 4C). As ex-
pected, levels of highly differentiated cells increased significantly
in the groups with higher antibody titers, but the differences were
not statistically significant when only CMV-seropositive individ-
uals were compared. Surprisingly, a significant reduction in the
absolute numbers of CD4 naïve T cells and an almost complete
absence of CD8 naïve T cells were found in comparisons of all
elderly individuals and those who were CMV seropositive. This
may be due to some homeostatic mechanisms that limit the gen-
eration of new naïve T cells in order to maintain the levels of total
T lymphocytes. In fact, in a comparison of the counts of T lym-
phocytes, those of the three groups of CMV-infected individuals
were very similar and higher than those of CMV-seronegative in-
dividuals (Fig. 4D), despite the notable increase in CD28null cells.
We also found a gradual reduction in CD4 and an increase in
CD8 T cells as the antibody titers rose.
FIG 4 Grouping of young and elderly subjects by anti-CMV antibody titer. (A) Distribution of frequencies of anti-CMV antibody titers in young and elderly
subjects and classification into groups defined according to the antibody levels in young people (50th and 95th percentiles). (B) Comparisons of naïve and
CD28null T cells (CD4 andCD8) between young and elderly individuals with similar anti-CMVantibody titers. Differences in themedian frequencies between
the young and the elderly in each group are represented by lines. Significant differences between subsets, assessed by Student’s t test or theMann-Whitney U test,
are indicated. (C) Absolute counts of naïve and CD28null T cells (CD4 and CD8) in elderly subjects. The Kruskal-Wallis test was used to identify significant
differences in frequencies between groups. “*p” indicates a significant difference in comparisons of all groups; “**p” indicates a significant difference when only
groups of CMV-seropositive subjects were considered. (D) Absolute counts of CD3 T cells, distributed into CD4 (white bars) and CD8 (black bars),
belonging to each group in elderly subjects.
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Overall, differences between elderly and young individuals in
highly differentiated and naïve CD4 T cells increased with their
anti-CMV antibody titers. The reduction in naïve cells may be a
strategy to compensate for the expansion of differentiated cells
and to avoid an increase in the total number of T cells.
Genetic features of CMV-infected elderly people. To identify
factors favoring CMV reactivation or the poor control of the in-
fection, which may be responsible for the higher antibody titers,
we analyzed some genetic characteristics of elderly individuals.
AlthoughHLA-DRB1 alleles are associated with increased suscep-
tibility to CMV pathologies in HIV-infected and transplant pa-
tients, we were unable to find any associations between levels of
anti-CMV antibody and the HLA-DRB1 profile of the elderly do-
nors (data not shown).
Conversely, TNF- is a key mediator in the reactivation of
CMV, as well as a differentiation factor associated with the loss of
expression of CD28 in T lymphocytes (20).Mutations in this gene
leading to over- or underexpression of the cytokinemay be signif-
icant in reactivation and the immune response against the virus.
We studied the SNP at position308 (G/A), which has functional
effects on gene transcriptional activity, whereby 308A* is a
stronger transcriptional activator than308G* after in vitro lym-
phocyte stimulation (21). Sixty (65.2%) elderly individuals had
the GG, 27 (30%) the GA, and 5 (5.5%) the AA genotype. These
are frequencies similar to those described for our population.
There were no overall differences in the frequency of CMV sero-
positivity or the anti-CMV antibody titers between the TNF-
genotype groups.
We nevertheless tested the levels of TNF- and IL-15, a cyto-
kine that could have a significant role in the proliferation of
CD28null T cells, in the sera of the CMV-seropositive elderly indi-
viduals. Again, no association was found between CMV antibody
titers and TNF- levels (Fig. 5A). However, IL-15 levels were pos-
itively correlated with antibody titers (Spearman test; rho 0.532
and P
 0.001), although they were undetectable in 60.4% of the
elderly individuals analyzed (Fig. 5B).
Our results suggest that anti-CMV antibody titers are not re-
lated to either HLA-DRB1 alleles or the 308 TNF- polymor-
phism in elderly individuals but are associated with serum IL-15
levels.
Response to vaccination and CMV infection. To determine
whether CMV serological status influences the ability to respond
to immunization in vivo, wemeasured the specific antibodies pro-
duced against influenza virus vaccination in the four groups of
elderly people. The production of specific antibodies to the vac-
cine diminished gradually and significantly in the groups of CMV-
seropositive individuals and was related to levels of anti-CMV
antibodies (comparisons within all groups, Kruskal-Wallis test;
P
 0.001; within CMV-seropositive groups, P 0.002) (Fig. 6).
The association between CD8 CD28null T cells and the response
to vaccination has been demonstrated previously (22). To verify
the influence of CMV seropositivity or the titer of anti-CMV an-
tibodies on the response to vaccination, we performed amultivar-
iate linear regression, including age and levels of CD8CD28null T
cells in elderly individuals as predictor variables (Table 2). It
should be noted that in both models, including CMV seropositiv-
ity and anti-CMV antibody titer, only CMV status and age
emerged as independent predictors of the magnitude of the hu-
moral response to influenza virus vaccination. The influence of
levels of CD8 CD28null T cells could not be determined in the
individuals studied. However, when the titer of anti-CMV anti-
bodies in all elderly individuals (CMV seronegative and CMV se-
ropositive)was included in themodel, CD8CD28null T cells were
also significantly associated (data not shown).
The in vivo ability to respond to new antigens is influenced by
both CMV infection and antibody titers in elderly individuals.
FIG 5 Levels of TNF- and IL-15 related to anti-CMV antibody titers. Spearman correlation coefficients and corresponding P values are shown in the upper
left-hand corner.
FIG 6 Response to influenza virus vaccination and its correlation with anti-
CMV antibody (Ab) titer. Anti-influenza virus antibody titers were quantified
by ELISA in the sera of elderly individuals after vaccination. The Kruskal-
Wallis test was used to compare the influenza antibody titer between CMV
groups. “*p” indicates a significant difference in comparisons between all
groups; “**p” indicates a significant difference when only groups of CMV-
seropositive subjects were considered.
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DISCUSSION
This study examined whether anti-CMV antibody titers in the
serum of young and elderly individuals are related to the pheno-
typic and functional status of their immune system. Our results
suggest a relationship between aging and CMV seropositivity fre-
quency and the levels of anti-CMV antibodies, which are clearly
associated with CMV-specific CD4 T cells in elderly individuals.
Moreover, both CMV seropositivity and antibody titers are re-
lated to the degree of differentiation of CD4 T cells and to the
IRP parameters of elderly people. Differences between elderly and
young individuals in highly differentiated and naïve CD4 T cells
increase depending on their anti-CMV antibody titers, and the
reduction in the frequency of naïve cells may be a strategy to com-
pensate for the expansion of differentiated cells and to avoid an
increase in the total number of T cells. Our results also suggest that
anti-CMV antibody titers are not related to HLA-DRB1 alleles or
to the TNF- polymorphism308 in elderly individuals but are
correlated with serum IL-15 levels. The in vivo ability of elderly
individuals to respond to new antigens is also influenced by CMV
infection.
The wide-ranging means of transmission of CMV lead to very
high seroprevalence, estimated to be between 30% and 90% in
developed countries, where it also increases with age (23). After
primary infection, the virus persists for the rest of an individual’s
life, most commonly in a latent form in a variety of tissues but
particularly in precursor cells of the monocytic lineage (24). Re-
activations from latency are likely to occur routinely in healthy
virus carriers and chronically in elderly individuals (3). The rela-
tionship between anti-CMV antibodies and the evolution of the
infection has been poorly understood.We found that elderly peo-
ple have higher levels of antibodies than young individuals. One
possible explanation for this is that titers of anti-CMV antibodies
are indicative of the history of infection, but this hypothesis could
be tested by analyzing other characteristics, such as time since
infection and the severity or frequency of reactivations. In this
way, while individuals with detectable CMV DNA in monocytes
have significantly higher percentages of anti-CMV-specific CD8
T cells, it has not been possible to determine the association with
anti-CMV antibody titers. However, the detection of CMV DNA
inmonocytes could be amarker of current CMV reactivation, and
the associated cellular responsemay reflect the expansion ofmem-
ory T cells to control the infection (25). In the present study, we
found that activation and proliferation of anti-CMVCD4T cells
in the elderly was associated with levels of specific antibodies.
These results are consistent with a recent paper (26) reporting a
correlated increase in humoral and CD4 T cell responses to
CMV antigens of extracellular origin in very old individuals. Fur-
thermore, we demonstrated a clear association between higher
levels of antibodies and a greater degree of CD4 T cell differen-
tiation in the elderly. The process of human immunosenescence,
irrespective of its association with CMV, induces important
changes in the T cell compartment. Although the two populations
ofCD8 andCD4Tcells undergo the sameprincipal phenotypic
shifts, the rates at which they occur or accumulate with age are
very different. CD4 T cells are more resistant than CD8 T cells
to phenotypic and functional changes with aging, probably be-
cause they have important regulatory roles and need to be sub-
jected to strict control mechanisms (27). In this way, there was an
association between titers of anti-CMV antibodies and the CD4
T cell phenotype in elderly but not in young individuals. This
might be explained by the different levels of antibodies in the two
age groups, but when we compared elderly and young individuals
with equal levels of anti-CMV antibodies, we found that, as ex-
pected, the differences were not explained solely by anti-CMV
antibody titers. Nevertheless, the changes were more pronounced
in CD4 than in CD8 T cells in the elderly, and there were sub-
stantial differences with young individuals with increasing anti-
body titers. The accumulation of highly differentiated cells may
not be the only reason for the changes in T cell phenotype, and the
impaired ability to replenish the pool of naïve T cells in elderly
individuals also contributes to this. In humans, a dramatic drop in
the absolute cell count of recent thymic emigrants with age is
evident (28). Despite this thymic degeneration, clinical lym-
phopenia is rare in elderly people and the number of circulating T
cells is maintained over the life span, probably due to the increase
in highly differentiated memory cells. Accordingly, we found that
higher anti-CMV antibody titers were correlated with lower abso-
lute counts of naïve and more highly differentiated T cells. How-
ever, there was no correlation with the total T lymphocyte count.
Experienced T lymphocytes may fill the immunological space and
homeostatic mechanisms block the generation of new naïve cells
to maintain the numbers of peripheral T lymphocytes. These
mechanisms make it difficult to preserve the T cell repertoire di-
versity that combats new pathogens as well as the host’s ability to
mount vigorous recall responses to recurrent infections (11). In-
deed, the loss of functionality with increasing differentiation and
the reduction in naïve cellsmay be responsible for the suppression
of immunity to other viruses and the impaired response to influ-
enza vaccination reported for elderly donors with CMV infection
(29). In this way, an insufficient antibody response following in-
fluenza vaccination in elderly individuals has also been linked to a
high frequency of CD8 CD28null T cells (22). In our study, both
CMV seropositivity and the titer of anti-CMV antibodies cor-
rected by age and CD8 CD28null T cells were independently as-
TABLE 2 Effect of CMV infection on response to influenza virus vaccination in elderly individuals, corrected by age and absolute counts of CD8
CD28null cellsa
Variable Regression coefficient SE 95% confidence interval P value
CMV seropositivity 15.24 5.083 25.3 to5.14 0.004
Age 0.437 0.233 0.9 to 0.027 0.064
CD8 CD28null (cells/l) 0.006 0.005 0.003 to 0.16 0.191
Anti-CMV antibody titer 0.011 0.003 0.017 to0.005 
0.001
Age 0.485 0.242 0.967 to0.002 0.049
CD8 CD28null (cells/l) 0.016 0.012 0.007 to 0.04 0.178
a Data from two regression models are given.
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sociated with the antibody response to influenza virus vaccina-
tion. The impaired response to new antigens may be considered a
marker of CMV infection-related immunosuppression, which has
other possible consequences. CMV seropositivity is strongly asso-
ciated with an IRP that is known to predict 2-year mortality in a
population-based sample of Swedish octogenarians (9). The IRP
may be summarized by the presence of expanded populations of
CD8 CD28null memory T cells and an inverted CD4/CD8 ratio
(30). Recently, two studies have reported that not only the CMV
infection but also the titer of CMV-specific antibodies is crucial
for determining the risk of increased mortality (31, 32). Differ-
ences related to CMV seropositivity in our study were more strik-
ing in CD28null T lymphocytes from elderly and young individu-
als, but only the CD4/CD8 ratio and the frequency of CD4
CD28null T cells were correlatedwith antibody titers, and again not
in the case of CD8 CD28null T cells of elderly individuals.
Themagnitude of CMV infectionmay be influenced by genetic
factors in the host. InHIV infection and renal transplantation, the
presence of HLA-DR7 has been correlated with an increased risk
of infection andCMVdisease andwith poor immune responses to
CMV (33, 34). It has been postulated that defective control of
infection in HLA-DR7 patients could lead to frequent virus reac-
tivations, contributing to the clonal expansion of specific subsets
of CD4 T cells restricted against a limited number of CMV anti-
gens (35). In our study, we found no association between titers of
anti-CMV antibodies and the HLA-DR alleles of the elderly indi-
viduals. Moreover, we found no association with their TNF-
polymorphisms, even though TNF- is considered to be a key
mediator of CMV reactivation. In turn, TNF-, which is aug-
mented by aging and CMV infection, induces CD28 expression
loss and T cell differentiation (36). Despite the high levels of anti-
CMV antibodies and the high frequencies of CD28null T cells, we
found no association between CMV infection and TNF- levels in
the sera of elderly individuals. There was a significant correlation
with the level of IL-15, another cytokine implicated in the loss of
CD28 expression in CD8 T cells and an inducer of preferential
proliferation and functional capabilities of CD4 CD28null T cells
(20, 37).
In summary, our data show that levels of anti-CMV antibodies
and CMV seropositivity are related to differentiation status and
immunocompetence in the elderly. Elevated anti-CMV antibody
titers could be a consequence rather than the cause of immunose-
nescence, but they may have value as a prognostic marker of the
deterioration of immunological status and the risk of age-related
diseases.
ACKNOWLEDGMENTS
This work was supported by the Red de Investigación Renal (REDinREN)
and FIS-Fondos FEDER European Union PI080566 and PI1202527 from
the Instituto Carlos III.
We thank Isabel Cuevas Pérez and José María Díaz Pérez for their
excellent technical assistance.
REFERENCES
1. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. 1998. High
incidence of active cytomegalovirus infection among septic patients. Clin.
Infect. Dis. 26:1076–1082.
2. Prösch S, Wendt CE, Reinke P, Priemer C, Oppert M, Kruger DH, Volk
HD, Docke WD. 2000. A novel link between stress and human cytomeg-
alovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV
activation. Virology 272:357–365.
3. Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser
R. 2007. Chronic herpesvirus reactivation occurs in aging. Exp. Gerontol.
42:563–570.
4. Aiello AE, Haan M, Blythe L, Moore K, Gonzalez JM, Jagust W. 2006.
The influence of latent viral infection on rate of cognitive decline over 4
years. J. Am. Geriatr. Soc. 54:1046–1054.
5. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI,
Cobbs CS. 2002. Specific localisation of human cytomegalovirus nucleic
acids and proteins in human colorectal cancer. Lancet 360:1557–1563.
6. Moro-Garcia MA, Alonso-Arias R, Lopez-Vazquez A, Suarez-Garcia
FM, Solano-Jaurrieta JJ, Baltar J, Lopez-Larrea C. 2012. Relationship
between functional ability in older people, immune system status, and
intensity of response to CMV. Age (Dordr.) 34:479–495.
7. Simanek AM, Dowd JB, Aiello AE. 2009. Persistent pathogens linking
socioeconomic position and cardiovascular disease in the US. Int. J. Epi-
demiol. 38:775–787.
8. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. 2011.
Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovas-
cular disease-related mortality in the United States. PLoS One 6:e16103.
doi:10.1371/journal.pone.0016103.
9. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG.
2000. Age-related change in peripheral blood T-lymphocyte subpopula-
tions and cytomegalovirus infection in the very old: the Swedish longitu-
dinal OCTO immune study. Mech. Ageing Dev. 121:187–201.
10. Goronzy JJ, Lee WW, Weyand CM. 2007. Aging and T-cell diversity.
Exp. Gerontol. 42:400–406.
11. Nikolich-Zugich J. 2008. Ageing and life-long maintenance of T-cell sub-
sets in the face of latent persistent infections. Nat. Rev. Immunol. 8:512–
522.
12. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A,
Betts MR, Freeman GJ, Vignali DA, Wherry EJ. 2009. Coregulation of
CD8 T cell exhaustion by multiple inhibitory receptors during chronic
viral infection. Nat. Immunol. 10:29–37.
13. Giunta S. 2008. Exploring the complex relations between inflammation
and aging (inflamm-aging): anti-inflamm-aging remodelling of inflamm-
aging, from robustness to frailty. Inflamm. Res. 57:558–563.
14. Alonso-Arias R, Moro-Garcia MA, Lopez-Vazquez A, Rodrigo L, Baltar
J, Garcia FM, Jaurrieta JJ, Lopez-Larrea C. 2011. NKG2D expression in
CD4 T lymphocytes as a marker of senescence in the aged immune
system. Age (Dordr.) 33:591–605.
15. Kang I, Hong MS, Nolasco H, Park SH, Dan JM, Choi JY, Craft J. 2004.
Age-associated change in the frequency of memory CD4 T cells impairs
long term CD4 T cell responses to influenza vaccine. J. Immunol. 173:
673–681.
16. Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen
JJ. 2001. T cell receptor excision circles as markers for recent thymic
emigrants: basic aspects, technical approach, and guidelines for interpre-
tation. J. Mol. Med. (Berl.) 79:631–640.
17. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two
subsets of memory T lymphocytes with distinct homing potentials and
effector functions. Nature 401:708–712.
18. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes
BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack
JA, Picker LJ, Koup RA. 1998. Changes in thymic function with age and
during the treatment of HIV infection. Nature 396:690–695.
19. Hadrup SR, Strindhall J, Kollgaard T, Seremet T, Johansson B, Pawelec
G, thor Straten P, Wikby A. 2006. Longitudinal studies of clonally
expanded CD8 T cells reveal a repertoire shrinkage predicting mortality
and an increased number of dysfunctional cytomegalovirus-specific T
cells in the very elderly. J. Immunol. 176:2645–2653.
20. Chiu WK, Fann M, Weng NP. 2006. Generation and growth of
CD28nullCD8 memory T cells mediated by IL-15 and its induced cyto-
kines. J. Immunol. 177:7802–7810.
21. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. 1997.
Effects of a polymorphism in the human tumor necrosis factor alpha pro-
moter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 94:
3195–3199.
22. Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I,
Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B.
2002. Lack of antibody production following immunization in old age:
associationwith CD8()CD28() T cell clonal expansions and an imbal-
ance in the production of Th1 and Th2 cytokines. J. Immunol. 168:5893–
5899.
Alonso Arias et al.
4494 jvi.asm.org Journal of Virology
 o
n
 April 26, 2017 by O
VIEDO
 LIBRARY
http://jvi.asm.org/
D
ow
nloaded from
 
23. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon
MJ. 2006. Seroprevalence of cytomegalovirus infection in the United
States, 1988–1994. Clin. Infect. Dis. 43:1143–1151.
24. Reeves M, Sinclair J. 2008. Aspects of human cytomegalovirus latency
and reactivation. Curr. Top. Microbiol. Immunol. 325:297–313.
25. Leng SX, Qu T, Semba RD, Li H, Yao X, Nilles T, Yang X, Manwani B,
Walston JD, Ferrucci L, Fried LP, Margolick JB, Bream JH. 2011.
Relationship between cytomegalovirus (CMV) IgG serology, detectable
CMV DNA in peripheral monocytes, and CMV pp65(495–503)-specific
CD8 T cells in older adults. Age (Dordr.) 33:607–614.
26. Vescovini R, Biasini C, Telera AR, Basaglia M, Stella A, Magalini F,
Bucci L, Monti D, Lazzarotto T, Dal Monte P, Pedrazzoni M, Medici
MC, Chezzi C, Franceschi C, Fagnoni FF, Sansoni P. 2010. Intense
antiextracellular adaptive immune response to human cytomegalovirus in
very old subjects with impaired health and cognitive and functional status.
J. Immunol. 184:3242–3249.
27. Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang
ZZ, Ouslander JG, Weyand CM, Goronzy JJ. 2008. T cell subset-specific
susceptibility to aging. Clin. Immunol. 127:107–118.
28. McFarland RD, Douek DC, Koup RA, Picker LJ. 2000. Identification of
a human recent thymic emigrant phenotype. Proc. Natl. Acad. Sci. U. S. A.
97:4215–4220.
29. Trzonkowski P, Mysliwska J, Pawelec G, Mysliwski A. 2009. From bench
to bedside and back: the SENIEUR Protocol and the efficacy of influenza
vaccination in the elderly. Biogerontology 10:83–94.
30. Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F.
2002. Expansions of peripheral blood CD8 T-lymphocyte subpopulations
and an association with cytomegalovirus seropositivity in the elderly: the
Swedish NONA immune study. Exp. Gerontol. 37:445–453.
31. Strandberg TE, Pitkala KH, Tilvis RS. 2009. Cytomegalovirus antibody
level and mortality among community-dwelling older adults with stable
cardiovascular disease. JAMA 301:380–382.
32. Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B,
McDyer JF, Semba RD, Casolaro V, Walston JD, Fried LP. 2010.
Cytomegalovirus infection and the risk of mortality and frailty in older
women: a prospective observational cohort study. Am. J. Epidemiol. 171:
1144–1152.
33. Kraat YJ, Christiaans MH, Nieman FH, van den Berg-Loonen PM, van
Hooff JP, Bruggeman CA. 1993. Increased frequency of CMV infection in
HLA-DR7 matched renal allograft recipients. Lancet 341:494–495.
34. Schrier RD, Freeman WR, Wiley CA, McCutchan JA. 1995. Immune
predispositions for cytomegalovirus retinitis in AIDS. The HNRCGroup.
J. Clin. Invest. 95:1741–1746.
35. Alonso-Arias R, Lopez-Vazquez A, Diaz-Pena R, Sampere A, Tricas L,
Asensi V, Rodrigo L, Lopez-Larrea C. 2009. CD8dim and NKG2D ex-
pression defines related subsets of CD4 T cells in HIV-infected patients
with worse prognostic factors. J. Acquir. Immune Defic. Syndr. 51:390–
398.
36. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM,
Goronzy JJ. 2005. Modulation of CD28 expression with anti-tumor
necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum.
52:2996–3003.
37. Alonso-Arias R, Moro-Garcia MA, Vidal-Castineira JR, Solano-
Jaurrieta JJ, Suarez-Garcia FM, Coto E, Lopez-Larrea C. 2011. IL-15
preferentially enhances functional properties and antigen-specific re-
sponses of CD4CD28(null) compared to CD4CD28 T cells. Aging
Cell 10:844–852.
Anti-CMV Antibody Titers and Immunocompetence
April 2013 Volume 87 Number 8 jvi.asm.org 4495
 o
n
 April 26, 2017 by O
VIEDO
 LIBRARY
http://jvi.asm.org/
D
ow
nloaded from
 
Intensity of the Humoral Response to Cytomegalovirus Is Associated
with the Phenotypic and Functional Status of the Immune System
R. Alonso-Arias,a M. A. Moro-García,a A. Echeverría,a J. J. Solano-Jaurrieta,b F. M. Suárez-García,c C. López-Larreaa,d
Immunology Department, Hospital Universitario Central de Asturias, Oviedo, Spaina; Internal Medicine and Geriatrics Department, Hospital Monte Naranco, Oviedo,
Spainb; Consejería de Salud y Servicios Sanitarios del Principado de Asturias, Oviedo, Spainc; Fundación Renal “Iñigo Alvarez de Toledo,” Madrid, Spaind
Volume 87, no. 8, p. 4486–4495, 2013. Page 4486: The byline should appear as shown above.
Page 4494, Acknowledgments, paragraph 1, lines 2 and 3: “PI1202527 from the Instituto Carlos III” should read “PI1202587 from the
Instituto Carlos III (SPAIN).”
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.01378-13
AUTHOR’S CORRECTION
8816 jvi.asm.org Journal of Virology p. 8816 August 2013 Volume 87 Number 15
